Increased overall survival for patients with glioma brain tumours is associated with mutations in the metabolic regulator isocitrate dehydrogenase 1 (IDH1). Gliomas develop within a mechanically challenged microenvironment that is characterized by a dense extracellular matrix (ECM) that compromises vascular integrity to induce hypoxia and activate HIF1α. We found that glioma aggression and patient prognosis correlate with HIF1α levels and the stiffness of a tenascin C (TNC)-enriched ECM. Gain-and loss-of-function xenograft manipulations demonstrated that a mutant IDH1 restricts glioma aggression by reducing HIF1α-dependent TNC expression to decrease ECM stiffness and mechanosignalling. Recurrent IDH1-mutant patient gliomas had a stiffer TNC-enriched ECM that our studies attributed to reduced miR-203 suppression of HIF1α and TNC mediated via a tension-dependent positive feedback loop. Thus, our work suggests that elevated ECM stiffness can independently foster glioblastoma aggression and contribute to glioblastoma recurrence via bypassing the protective activity of IDH1 mutational status.
Increased overall survival for patients with glioma brain tumours is associated with mutations in the metabolic regulator isocitrate dehydrogenase 1 (IDH1). Gliomas develop within a mechanically challenged microenvironment that is characterized by a dense extracellular matrix (ECM) that compromises vascular integrity to induce hypoxia and activate HIF1α. We found that glioma aggression and patient prognosis correlate with HIF1α levels and the stiffness of a tenascin C (TNC)-enriched ECM. Gain-and loss-of-function xenograft manipulations demonstrated that a mutant IDH1 restricts glioma aggression by reducing HIF1α-dependent TNC expression to decrease ECM stiffness and mechanosignalling. Recurrent IDH1-mutant patient gliomas had a stiffer TNC-enriched ECM that our studies attributed to reduced miR-203 suppression of HIF1α and TNC mediated via a tension-dependent positive feedback loop. Thus, our work suggests that elevated ECM stiffness can independently foster glioblastoma aggression and contribute to glioblastoma recurrence via bypassing the protective activity of IDH1 mutational status.
Malignant gliomas are a highly heterogeneous group of brain tumours that exhibit diverse invasiveness, aggressiveness and treatment responsiveness. Diffuse lower-grade gliomas ( LGGs, World Health Organization (WHO) grades II and III) demonstrate highly variable clinical behaviour ranging from indolent to rapidly progressive 1 .
LGGs often recur as glioblastomas (GBMs, WHO grade IV glioma), which are inarguably the most advanced and lethal adult brain tumour, with poor treatment responsiveness and a high recurrence rate contributing to poor patient outcome.
Mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) characterize the majority of LGGs and a small percentage of GBMs, and define subtypes that associate with better responses to radiation treatment and an improved prognosis compared with gliomas with wild-type (WT) IDH [1] [2] [3] [4] . Oncogenic IDH mutations divert metabolic flux resulting in high levels of (R)-2-hydroxyglutarate, an onco-metabolite implicated in hypoxiainducible factor 1 alpha (HIF1α) stability, epigenetic modifications and extracellular matrix (ECM) remodelling 5 . The relationship between IDH mutations and downstream HIF1α signalling remains unclear with conflicting reports suggesting elevated HIF1α protein in IDH-mutant tumours 6 or, conversely, blunted hypoxia sensing through HIFα mediated by elevated activity of prolyl 4-hydroxylases 7 . As tumours are characterized by altered tissue-level and cellular mechanics, including ECM remodelling and stiffening, and a stiffened ECM can compromise blood vessel integrity to induce hypoxia and activate HIF1α (refs 8-10), we investigated the interplay between IDH1 mutation status, ECM mechanics, HIF1α signalling and GBM aggression.
RESULTS

ECM stiffness associates with IDH1 mutations in primary tumours
To determine whether glioma aggression associates with ECM stiffness, we utilized atomic force microscopy (AFM) to quantify the stiffness 11 of the ECM in a cohort of fresh-frozen human brain biopsies representing non-tumour gliosis, de novo (primary) LGGs (WHO grades II and III) and de novo primary GBMs (WHO grade IV). We determined that gliotic tissue had the lowest ECM stiffness (Young's modulus, E; 10-180 Pa) while LGGs (50-1,400 Pa) and GBMs (70-13,500 Pa) were progressively stiffer (Fig. 1a) . Consistent with the elevated ECM stiffness, mechanosignalling increased progressively from gliotic tissue to the stiffer GBMs, as indicated by higher phosphorylated focal adhesion kinase (pFAK residue Tyr397) and myosin light chain 2 (pMLC2 residue Ser19) (Fig. 1b) . NanoString nCounter gene expression analysis 12 of an outcome-predictive gene cluster 13 (aggressiveness binned on a scale of 1-10 with 1 indicating the most aggressive) of human GBM tissue biopsies indicated a significant correlation between the proportion of highly stiff areas within a GBM tissue (E > 1,400 Pa) and worst patient prognosis score (Fig. 1c, red) . By contrast, those tissues that contained a high proportion of soft ECM regions (E < 200 Pa) had the best patient prognosis score 13 ( Fig. 1c, blue) .
Interestingly, despite a strong overall correlation between ECM stiffness and glioma grade, relatively stiff and compliant subsets of patient tumours were evident in both the LGG and GBM samples. To explore this finding, we assessed the IDH1 mutational status in our cohort of patient samples. Mutations in IDH genes characterize the majority of LGGs and a small percentage of GBMs [1] [2] [3] [4] . For both the LGG and GBM samples, we noted that the stiffness of the ECM in the R132H IDH1 tumours was significantly less than the ECM measured in the WT IDH1 tumours (Fig. 1d,e) . To this end, the R132H IDH1 GBM samples exhibited mechanical characteristics more concordant with the LGG samples (Fig. 1d,e) . R132H IDH1 GBM samples also had lower pFAK and pMLC2 levels, reflecting reduced mechanosignalling (Fig. 1f ). These data demonstrate that ECM stiffness correlates with glioma aggression and that IDH1 mutational status associates with a softer ECM, regardless of histological grade.
TNC modifies ECM stiffness and mechanosignalling
To examine the relationship between IDH mutation and ECM stiffness, we used a candidate approach to profile major ECM constituents in GBM, hyaluronic acid (HA), and HA-interacting molecules 14, 15 . Immunohistochemistry revealed that the elevated ECM stiffness in the patients with poorer prognosis was accompanied by a substantial increase in HA expression as well as increased levels of TNC, and indicated that these levels increased progressively from gliosis to LGGs and to the GBMs ( Fig. 2a and Supplementary  Fig. 2a,b ) 16 . Importantly, ECM stiffness did not correlate with levels or distribution of type I collagen, vasculature or cellularity ( Supplementary Fig. 1a-g ). Indeed, a survey of the ECM status of the softer ECMs in the IDH1-mutant human GBM biopsies revealed a reduction in the levels of TNC (Fig. 2b) . Further, bioinformatics analysis of publicly available messenger RNA expression data 1 revealed a significant correlation between IDH1 mutational status and TNC expression in LGG tumours, with stratification of LGG patients by TNC upregulation revealing reduced patient survival (Fig. 2c,d) .
Similarly, IDH1 mutational status correlated significantly with TNC mRNA expression in GBM 17, 18 tumours (Fig. 2e) . NanoString nCounter gene expression analysis 12 of TNC expression (where lower scores correspond to lower expression) in GBM samples yielded a significant correlation between TNC and the tumour aggressiveness score derived via the outcome-predictive gene expression signature (where lower scores correlated with reduced overall survival, Fig. 2f ).
Consistent with a relationship between IDH1 mutational status, ECM stiffness and glioma aggression, ectopic expression of the R132H IDH1 mutation significantly improved the survival of nude mice bearing xenografts derived from either primary GBM cells or the U87 cell line (Fig. 2g and Supplementary Fig. 2c,d ). The resultant tumours were also softer and exhibited reduced mechanosignalling, as revealed by decreased pMLC2 and pFAK ( Fig. 2h and Supplementary Fig. 2e,f) . In both the primary and U87 xenograft models, we noted that the softer IDH1-mutant-expressing GBM tumours had low to negligible TNC expression ( Fig. 2i and Supplementary Fig. 2g ).
To experimentally test the role of TNC in ECM stiffness and glioma aggression, we knocked down TNC in primary GBM cells (WT IDH1, Supplementary Fig. 2h,i) and assessed the resulting effects on ECM stiffness and tumour aggression. Nude mice injected orthotopically with GBM cells with short hairpin RNA (shRNA)-reduced TNC not only survived longer (Fig. 2j ), but the tumours were softer and had lower mechanosignalling, as revealed by reduced pFAK and pMLC2 (Fig. 2k,l ). These findings demonstrate that TNC can impact glioma aggression by increasing ECM stiffness and suggest a molecular role for IDH1 mutational status in perturbing this relationship.
HIF1α directly regulates TNC expression
Interestingly, we noted that compliant ECM regions in xenograft tumours with TNC knocked down ( Fig. 2j-l) had reduced HIF1α expression 19 ( Supplementary Fig. 3a,b) . Previous work implicated hypoxia and HIF1α signalling in TNC expression 20, 21 . A bioinformatics analysis revealed a strong correlation between TNC mRNA upregulation and expression of hypoxia-induced genes in both WT and R132H IDH1 patient GBMs (Fig. 3a) , and expression of carbonic anhydrase 9 (CA9), a HIF1α-target gene, was reduced in R132H tumours (Fig. 3b) . Accordingly, we explored the relationship between GBM aggression and HIF1α-induced TNC expression.
TNC protein expression increased in (WT IDH1) human GBM cells cultured in vitro under hypoxia ( Fig. 3c and Supplementary  Fig. 3d,e) . shRNA-mediated knockdown of HIF1α reduced hypoxiadependent induction of TNC ( Supplementary Fig. 3c-f) . To investigate the role of reduced HIF1α expression in vivo, we orthotopically injected the WT IDH1 primary GBM cells with shRNA-reduced HIF1α. Consistent with a direct link between HIF1α and TNC expression, reducing HIF1α expression increased survival and reduced mechanosignalling (Fig. 3d,e) . Importantly, reducing HIF1α expression significantly correlated with reduced TNC mRNA and protein expression levels (Fig. 3f,g ).
To determine whether HIF1α directly regulates TNC expression, we identified putative hypoxia-response elements in the promoter of TNC (provided in the Methods). We performed chromatin immunoprecipitation assays using HIF1α as the bait in WT IDH1 human GBM cells and found that HIF1α binds directly to the LGG human patient samples as measured by AFM (two-sided KolmogorovSmirnov test yielded P = 4.8 × 10 −5 ). (e) Distribution of ECM stiffness in WT IDH1 (n = 6 patient samples) and R132H IDH1 (n = 5 patient samples) primary GBM human patient samples as measured by AFM (two-sided Kolmogorov-Smirnov test yielded P = 6.5 × 10 −5 ). (f) Immunofluorescence images and quantification for pMLC2 (green, left) and pFAK397 (green, right) with DAPI (blue) for the tumours shown in e (mean ± s.e.m., n = 6 patient samples for WT IDH1 and n = 5 patient samples for R132H IDH1, two-sided unpaired t-test where * * P = 0.007, * * * * P = 0.0006). Scale bars, 50 µm. LGG and primary GBM patient samples (mean ± s.e.m., n = 5 patient samples per group, twosided unpaired t-test, * * * P = 0.00032). (b) Immunofluorescence images and quantification for TNC with DAPI in WT IDH1 and R132H IDH1 primary LGG and primary GBM patient samples (mean ± s.e.m., n = 5 patient samples per group, two-sided unpaired t-test, * * P = 0.0031 for LGG and * * * P = 0.0008 for GBM). (c) The Cancer Genome Atlas (TCGA) data analysed for TNC upregulation in WT (n = 64 patients) and R132H IDH1 (n = 219 patients) human tumours (mean ± s.d., z-score threshold ±1.0, Mann-Whitney U-test, * * * P < 0.0001). (d) Patient survival stratified by TNC status (TNC upregulation (n = 45 patients), TNC unchanged (n = 468 patients), z-score threshold ±1.0, log-rank/Mantel-Cox test, * * * * P < 0.0001). (e) TCGA data analysed for relative TNC expression in WT (n = 199 patients) and R132H (n = 12 patients) IDH1 human tumours (mean ± s.d., Wilcox/Mann-Whitney U-test, * * * * P = 4 × 10 −4 ). (k) Distribution of ECM stiffness in xenograft tumours derived from WT IDH1 primary human GBM cells expressing either a control scramble shRNA (red) or shRNA targeting TNC (grey) (n = 6 mice per group, n was used to derive statistics, histogram encompasses all the measurements across all regions of all six mice, two-sided Kolmogorov-Smirnov test, P = 1.73 × 10 −2 ). (l) Immunofluorescence images and quantification for pFAK397 ( * * * P = 0.0008) and pMLC2 ( * P = 0.009) with DAPI in xenograft tumours expressing control scramble shRNA or shRNA targeting TNC (mean ± s.e.m., n = 4 mice per group, two-sided unpaired t-test). Scale bar, 50 µm. 
R132H IDH1 primary GBMs cannot tune HIF1α
The presence of the IDH1 mutation could enhance GBM patient survival by increasing the production of the onco-metabolite (R)-2-hydroxyglutarate, which can induce genome-wide methylation alterations and alter cellular redox state to promote cellular transformation 5, 22 . IDH1 could also influence tumour phenotype by regulating HIF1α (refs 6,7,23,24) . Analysis of WT and R132H IDH1 GBM xenografts revealed that R132H IDH1 tumours had low to barely detectable nuclear HIF1α (and TNC) despite evident necrosis (asterisks) and hypoxia ( Fig. 4a and Supplementary Fig. 3g ).
Immunoblot analysis confirmed that the IDH1-mutant GBMs had significantly reduced total tissue HIF1α protein (Fig. 4b) suggesting a profound dysregulation of the hypoxic response in xenograft tumours expressing the R132H IDH1 mutation.
Experimentally, we observed a lack of upregulation of either HIF1α or TNC in R132H IDH1 GBM cells cultured in vitro under hypoxia, a finding that was recapitulated with experimental models endogenously expressing R132H IDH1 ( Fig. 4c and Supplementary  Fig. 4a -c). When we ectopically expressed a constitutively active HIF1α (CA-HIF) 25 in the R132H IDH1 cells, we found a robust IDH1 primary human GBM cells expressing either a vector control (CNL, orange, n = 10 mice) or a constitutively active HIF1α (CA-HIF, grey, n = 9 mice, log-rank (Mantel-Cox) test, * P = 0.0482). (e) Immunofluorescence images and quantification for TNC (red) in xenograft tumours derived from either CNL or CA-HIF-expressing R132H IDH1 primary human GBM cells (mean ± s.d., n = 3 mice per group, two-sided unpaired t-test, * P = 0.0260). (f) Immunoblot and quantification of pFAK397 (n = 3 mice per group, two-sided unpaired t-test, * * P < 0.0044) and pMLC2 (mean ± s.d., n = 3 mice per group, two-sided unpaired t-test, * * P < 0.0121) protein expression in CNL and CA-HIF1α xenografts normalized to total FAK and MLC2, respectively, and β-actin loading control, and represented as percentage of expression of CNL tumours (n = 3 mice per group). Scale bars, 50 µm. Unprocessed original scans of blots are shown in Supplementary  Fig. 7 .
upregulation of TNC expression both under normoxia and hypoxia ( Fig. 4c and Supplementary Fig. 4c ). Importantly, survival was decreased in mice bearing orthotopic R132H IDH1 GBM tumours expressing the constitutively active HIF1α (CA-HIF) compared with vector-only tumours (Fig. 4d) . Consistently, both mechanosignalling and TNC were elevated in constitutively active HIF1α tumours (Fig. 4e,f) . These data suggest that the R132H IDH1 mutation blunts hypoxia sensing to reduce HIF1α-dependent TNC expression, and provide a potential explanation for why patients bearing tumours with mutations in IDH experience improved survival. Luciferase reporter assay performed on WT IDH1 cells using the wild-type (red) and mutated (black) 3 UTR consensus sites on HIF1α mRNA (left, three seed sequences) and on TNC mRNA (right, two seed sequences) normalized by secreted alkaline phosphatase levels; each group is graphed relative to its respective mutated group (mean ± s.e.m., n = 4 biological replicate samples, two-sided paired t-test, for HIF1α: * * P = 0.0048, seed 1; * P = 0.0343, seed 2; * * P = 0.0128, seed 3; for TNC: * P = 0.0286, seed 1; NS (not significant) P = 0.1071, LGG to GBM, n = 5 patients and * * * P = 0.0034; for GBM to GBM, n = 3 patients and * * * P = 0.0006). (h) Graphic depicting a model of ECM stiffness-driven repression of miR-203 expression to activate HIF1α/TNC. Scale bars, 50 µm.
Mechanosignalling promotes R132H IDH1 tumour aggression
While IDH mutations may confer prolonged survival in glioma patients suffering from gliomas, IDH-mutation-bearing gliomas still frequently recur despite surgical resection and treatment 26, 27 . Standard of care for GBM patients involves surgical resection followed by high-dose radiation treatment and chemotherapy. These treatment modalities can cause dramatic changes in the post-treatment tumour microenvironment, including the deposition and remodelling of ECM molecules, which we and others have shown to be associated with stromal stiffening 28 . Accordingly, we asked whether the posttreatment (secondary) IDH1-mutant GBMs were stiffer than the patient-matched primary LGG or GBM tumours. AFM analysis of secondary IDH1-mutant patient GBMs revealed highly stiff ECMs that were significantly stiffer than those measured in primary IDH1-mutant GBMs and were as stiff, if not stiffer, than those measured in primary WT IDH1 GBMs (Fig. 5a left compared with Fig. 1e) . Indeed, mechanical analysis of patient-matched IDH1-mutant GBM pairs, at initial diagnosis (primary tumour) and at recurrence (secondary tumour excised after treatment with gamma radiation and temozolomide chemotherapy), revealed a remarkable increase in the stiffness of the associated ECMs in the secondary IDH1-mutant GBMs (Fig. 5a, right) . Further, we noted a strong increase in TNC expression in secondary tumours for both LGG and GBM patient cohorts (Fig. 5b) .
As such, we explored whether we could increase the aggression of R132H IDH1 GBM cells by enhancing mechanosignalling through plating the cells on a stiff substrate. We plated the R132H IDH1 GBM cells on two-dimensional polyacrylamide (PA) gels with a calibrated stiffness ranging from very soft (140 Pa, representing normal brain 29, 30 ) to stiff (6,000 Pa, representing the upper range of elastic moduli in GBM samples, as presented in Fig. 1d ). We compared their characteristic cell spreading behaviour and found that R132H IDH1 cells spread better on stiff substrates (Fig. 5c ). When R132H IDH1 cells were subjected to hypoxia, they showed a robust upregulation of HIF1A, TNC and Glut1 expression (Fig. 5d) . By contrast, when plated on a soft substrate analogous to the soft ECMs we measured in vivo, they showed a blunted hypoxia sensing response (Fig. 5d) . These findings indicate that a stiffened ECM overrides the blunted hypoxia sensing conferred by expression of the mutant R132H IDH1.
To directly assess whether enhancing mechanosignalling could override the blunted hypoxia sensing conferred by the R132H IDH1 gene, we ectopically expressed an auto-clustering β1 integrin mutant (V737N) in the R132H IDH1 cells to recapitulate downstream stiffness-dependent mechanosignalling through elevation of FAK signalling 29 . We found that R132H IDH1 GBM cells expressing the auto-clustering V737N mutated β1 integrin spread similarly on the soft and stiff substrates (Fig. 5c ). Consistent with cell spreading, V737N R132H IDH1 GBM cells responded to hypoxia largely independently of the underlying substrate stiffness with robust increases in HIF1α, TNC and Glut1 expression levels on both soft and stiff substrates (Fig. 5d) . These data indicate that ECM stiffness can induce HIF1α and suggest that the relationship between IDH1 mutation and hypoxia sensing through HIF1α may be largely dependent on the stiffness of the ECM microenvironment of the tissue.
We performed xenograft injections of R132H IDH1 cells expressing either WT or V737N β1 integrin to test whether enhancing cellular mechanosignalling in mutant GBMs would increase tumour aggression and, if so, whether this increase would be associated with elevated HIF1α and TNC expression. Survival was decreased in mice bearing the V737N β1 tumours compared with WT β1 tumours (Fig. 5e) . Tumours derived from R132H IDH1 GBM cells expressing the V737N integrin demonstrated increased mechanosignalling (Fig. 5f) , and expressed elevated levels of both HIF1α and TNC (Fig. 5g) . In contrast, R132H IDH1 GBM tumours expressing WT β1 integrin had low to negligible HIF1α and TNC protein expression, despite pronounced hypoxia (Fig. 5g) . Interestingly, V737N tumours were substantially stiffer than control tumours (Fig. 5h) , suggesting a positive feedback whereby elevated mechanosignalling increases TNC expression to increase ECM stiffness. These findings further link GBM aggression to tissue mechanics, and suggest that elevated mechanosignalling can bypass the protective activity imparted by the R132H IDH1 to promote tumour aggression.
miR-203 targets HIF1α and TNC
Next, we explored the putative positive feedback whereby elevated mechanosignalling increases TNC expression to increase ECM stiffness. We previously found that ECM stiffness regulates microRNA expression to alter tumour progression, including miR-203, a microRNA implicated in GBM aggression, recurrence, and treatment responsiveness 9, [31] [32] [33] [34] . We found that R132H IDH1 cells expressed fivefold higher levels of miR-203 on soft PA gels compared with stiff gels (Fig. 6a) . Further, we identified several putative consensus sites in the 3 UTRs of both HIF1α and TNC mRNA ( Supplementary  Fig. 5a ). Consistent with the hypothesis that tissue mechanics may induce HIF1α and TNC in GBMs expressing the mutant IDH1 by reducing levels of miR-203, reporter assays using the wild-type and mutated 3 UTR consensus sites confirmed that miR-203 interacts with and inhibits HIF1α transcription at three out of three predicted sites and TNC at one of two predicted sites (Fig. 6b ). Experimentally, we tested whether antagomiR-mediated knockdown 35 of miR-203 could elevate HIF1α and TNC levels in R132H IDH1 GBM cells grown in culture (on a soft ECM where miR-203 levels are elevated) and in vivo (Supplementary Fig. 5b ). Consistent with a mechanistic interaction, we observed elevated HIF1α and TNC levels in R132H IDH1 GBM cells with reduced miR-203 (ant-203) compared with vector controls (Supplementary Fig. 5c,d) , with a significant correlation between their protein expression (Fig. 6c) . Importantly, orthotopically injected R132H IDH1 tumours with reduced miR-203 exhibited decreased survival (Fig. 6d) , increased TNC expression (Fig. 6e) , and elevated ECM stiffness (Fig. 6f) .
Next, we assessed the expression of miR-203 in our patientmatched primary and secondary tumours, using in situ and quantitative PCR, and found that the stiffer secondary tumours exhibited reduced miR-203 expression compared with their patient-matched primary tumour counterparts for patients who originally presented with either LGG or GBM tumours (Figs 5a and 6g) . Taken together, these data suggest that tumour therapy may contribute to the development of more aggressive IDH1-mutant GBMs by increasing ECM stiffness and reducing miR-203 expression (Fig. 6h) .
DISCUSSION
Here, we establish a clinically relevant role for ECM mechanics in glioma aggression. We link HIF1α-dependent hypoxia sensing and TNC expression with an aggressive tumour phenotype, and demonstrate that ECM stiffness directly represses miR-203 expression to activate HIF1α-dependent TNC deposition via a positive feedback loop. The relationship between IDH1 mutations and HIF1α is controversial 6, 7, 24, 36, 37 . Our studies highlight the cellular plasticity and sensitivity of R132H IDH1 GBM cells to ECM stiffness and oxygen tension. In all likelihood, mutations in IDH1 will exert a myriad of context-dependent effects to varying consequence depending on the origin of the tumour, the stage of the disease, the oxygen tension within the tumour and the duration of the disease. Gainof-function IDH mutations often induce a CpG island methylator phenotype (G-CIMP) 22, 38 that is associated with improved outcome 38 . IDH mutations are most prevalent in LGG, which, as a result of being less proliferative and diffusely infiltrative, may be less hypoxic than higher-grade GBMs 1, 39, 40 . Therefore, LGGs frequently have a relatively long disease course where the long-term effect of IDH mutations (global DNA hypermethylation) is likely to dominate LGG pathobiology. On the contrary, for the rapidly progressing GBMs, the acute effects of IDH1 mutation may profoundly dictate GBM cell behaviour. Our work presents an example of one mechanism, outside of the sustained effects imparted by hypermethylation, whereby expression of the mutant IDH1 can compromise HIF1α induction in response to hypoxia to modify the ECM and alter tissue mechanics and tumour aggression. Our findings suggest that ECM mechanics provides putative promising targets for therapeutic interventions aimed at disabling biomechanically driven pathways that intersect with glioma aggression to enhance treatment efficacy, delay disease progression, and improve patient survival.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3429
Human samples. Human tissue samples, lacking any patient-identifying information, were either collected under approved study (protocol number 11-07588) and in accordance with the University of California, San Francisco Committee on Human Research policy, or obtained from the University of California, San Francisco Brain Tissue Bank. All human tissue samples were collected in compliance with informed consent policy. Being fully aware of the histopathological heterogeneity of glioblastoma 'multiforme' , we performed a meticulous region-to-region analysis correlating the mechanical properties of the patient gliosis and tumour samples underlying Fig. 1 . We worked with a pathologist to identify specific regions within the patient samples to correlate ECM stiffness with mechanosignalling in adjacent sections. In H&E-stained serial sections, distinct regions (varying from approximately 1-3 mm 2 in area) of the patient tumours were pathologist identified, with care taken to avoid vasculature and adjacent non-malignant tissue. Stiffness (as measured by AFM), immunostaining and in situ hybridization analyses were performed in regionmatched adjacent serial sections.
Mouse studies. All mice were maintained in accordance with University of California Institutional Animal Care and Use Committee (IACUC) guidelines under protocol number AN109372-01. For all mouse xenograft studies, an hour before intracranial injection, cells were washed once with PBS solution, collected by trypsinization, counted, and re-suspended in PBS at 100,000 cells per microlitre. For intracranial injections, 5-6-week-old NCR nude female mice were anaesthetized with 2% isoflurane, injected subcutaneously with buprenorphine (0.03 mg kg −1 ), and slowly injected with a 3 µl tumour cell suspension (300,000 cells per 3 µl injection) into the striatum, as described previously 41 . For TNC shRNA studies, TNC knockdown was induced by addition of 20 mM IPTG in the drinking water of mice for the duration of the entire experiment. Mice were euthanized when exhibiting 15% weight loss. For hypoxia experiments, mice were injected via intraperitoneal injection with 60 mg kg −1 hypoxyprobe 70 min prior to euthanization.
Immunostaining and immunoblotting.
Immunofluorescence and immunoblotting analysis were performed as described previously 29, 30 . For all immunoblotting, cells were lysed in RIPA or Laemmli buffer 42 . Antibodies used for immunofluorescence and immunoblotting analysis are listed below. Cell culture conditions. All cells were maintained at 37 • C and 5% CO 2 . Primary human GBM cells (GBM43) have been previously described 43 , and were cultured in Neurobasal-A media (Invitrogen) supplemented with B27 Supplement (Invitrogen), N2 Supplement (Invitrogen), 20 ng ml −1 epidermal growth factor (Peprotech), 20 ng ml −1 fibroblast growth factor (Peprotech), and 100 units ml −1 penicillin/streptomycin. U87 cells (obtained from and authenticated by ATCC) were grown in DMEM supplemented with 10% fetal bovine serum (Hyclone), 2 mM L-glutamine, and 100 units ml −1 penicillin/streptomycin. TS603 cells (harbouring endogenous R132H IDH1) and TS667 cells (expressing WT IDH1) have been previously described 44 , and were grown in Neurobasal-A media (Invitrogen) supplemented with B27 Supplement (Invitrogen), N2 Supplement (Invitrogen), 20 ng ml −1 epidermal growth factor (Peprotech), 20 ng ml −1 fibroblast growth factor (Peprotech), 20 ng ml −1 platelet-derived growth factor AA (Peprotech), and 100 units ml −1 penicillin/streptomycin. BT142 cells harbouring endogenous R132H were obtained from and authenticated by ATCC, and were grown in Neurobasal-A media (Invitrogen) supplemented with B27 Supplement (Invitrogen), N2 Supplement (Invitrogen), 20 ng ml −1 epidermal growth factor (Peprotech), 20 ng ml −1 fibroblast growth factor (Peprotech), 20 ng ml −1 platelet-derived growth factor AA (Peprotech), and 100 units ml −1 penicillin/streptomycin. All primary cells and cell lines were authenticated by ATCC (where applicable), or by analysis of morphological and phenotypic characteristics as well as gene and protein expression.
No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample. All primary cells and cell lines were tested for mycoplasma contamination using a commercially available kit (PCR-Mycoplasma Test Kit I/C (Promokine PK-CA91-1024), according to the manufacturer's instructions, at the onset of the work (tested negative) and have never exhibited contamination symptoms after initial testing. Derivative cells were transduced in vitro with a lentiviral vector-encoding firefly Luciferase and either eGFP (U87 lines) or mCherry (primary GBM lines) fluorescent proteins for combined bioluminescent imaging and flow sorting. For stable shRNA cell lines harbouring isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible transgenes, expression was induced with 100 µM IPTG five days before experimentation. For polyacrylamide hydrogel studies, cells were plated on fibronectin-conjugated gels for either 8 h (protein analysis) or 24 h (mRNA analysis) prior to harvesting cell lysates.
Quantitative real-time PCR and in situ hybridization. Total cellular RNA was isolated using the mirVana miRNA isolation kit (Life Technologies AM1560), according to the manufacturer's instructions. Reverse transcription was performed from 2 µg of total RNA using random primers (Amersham Biosciences). PCR reactions were performed in triplicate with LightCycler Fast Start DNA Master SYBR Green Mix (Roche) using a Realplex 29,30 epGradient S Mastercycler (Eppendorf) and the relative amount of cDNA was calculated by the comparative Ct method using the RPS20 ribosomal protein as a control. Primer sequences are: human TNC forward primer 5 -TCTCAGGGTCATTCACCACA-3 , human TNC reverse primer 5 -CA CCGTGCGTGTAATTTCTG-3 , human HIF1A forward primer 5 -CAGTCGACA CAGCCTGGATA-3 , human HIF1A reverse primer 5 -TGTCCTGTGGTGACTT GTCC-3 , SLC2A1 forward primer 5 -GGCATCAACGCTGTCTTCTA-3 , SLC2A1 R 5 -CAGCGAGGCCTATGAGGTG-3 , RPS20 forward primer 5 -AGGACCAGT TCGAATGCCTA-3 , and RPS20 reverse primer 5 -GATTCGATCAACTCAACTC CTG-3 .
For miRNA qPCR analysis, reverse transcription of specific miRNAs (from 10 ng of total RNA) was carried out using the real-time loop primers for each type of miRNA and the TaqMan miRNA in situ hybridization was performed as previously described using formalin-fixed, paraffin-embedded tissue sections (5 µm thickness) 45 . Atomic force microscopy measurements. Atomic force microscopy (AFM) and analysis were performed using an MFP3D-BIO inverted optical atomic force microscope mounted on a Nikon TE2000-U inverted fluorescent microscope (Asylum Research) as described previously ( Supplementary Fig. 1a ) 11 . Briefly, for pathologist-identified, regionally matched correlations between ECM stiffness and mechanosignalling, patient tissues were immunostained with multiple specific, patient-representative regions (4-10 regions per tumour) identified (with the xand y-coordinates noted and images acquired) for further AFM testing in serial sections ( Supplementary Fig. 6c left) . After patient tumour sections were secured for mechanical testing, the identified testing region was located via x-and y-coordinates using the optical microscope ( Supplementary Fig. 6c right) . Individual patient data were combined and graphed to depict correlations and the patient variability within the cohort(s) (Supplementary Fig. 6d,e) .
Nanostring nCounter gene expression signature assessment. NanoString nCounter gene expression analysis 12 of human GBM tissue biopsies was used to assess the 9-gene expression signature used as a surrogate for tumour aggressiveness 13 . Derived from a 38-gene predictor (validated as a significant predictor of overall survival), the top-ranked 9 genes were selected on the basis of the significance of survival association (fold change level) and technical considerations (including abundance and consistency of amplification of the target gene in FFPE samples) 13 . Aggressiveness reflects the overall survival prediction based on the meta-score calculated with the 9-gene signature 13 .
Lentivirus-mediated ectopic expression or knockdown. For ectopic expression or knockdown studies, lentiviral vectors (pLV lacI NeoR; gift from J. Lakins, UCSF, USA) were custom built to facilitate cloning of shRNA under inducible IPTG control. Briefly, oligonucleotides corresponding to validated shRNA from The RNAi Consortium (TRC) were designed and annealed to yield duplexes with 5 and 3 overhangs complementary to AgeI and EcoRI sites of the modified U6 promoter containing three lacO binding sites for the bacterial repressor protein lacI (Sigma). pLV lacI_NeoR also provides for constitutive nuclear expression via the human EEF1a promoter of lacI tagged at the N terminus with three tandem repeats of the 9E10 myc epitope and at the C terminus with a nuclear localization sequence from SV40 large T antigen. The latter is co-expressed with the neomycin phosphotransferase gene from a bicistronic mRNA via an internal ribosome entry site (IRES) to provide selection of transduced cells with G418. Utilized TNC shRNA was TRCN0000230788.
Preparation of polyacrylamide gels substrates. Glass and silicon substrates were prepared by glutaraldehyde activation followed by conjugation with 10 µg ml −1 (glass) or 20 µg ml −1 (silicon) fibronectin as described previously 29 . Polyacrylamide hydrogel substrates (soft: 2.5% acrylamide, 0.03% Bis-acrylamide; stiff: 10% acrylamide, 0.5% Bis-acrylamide) were prepared as previously described with one modification: functionalization with succinimidyl ester was with 0.01% N6, 0.01% Bis-acrylamide, 0.025% Irgacure 2959, and 0.002% di(trimethylolpropane) tetraacrylate (Sigma) 46 . Following functionalization with succinimidyl ester, hydrogels were conjugated overnight with 20 µg ml −1 fibronectin at 4 • C and rinsed twice with PBS and DMEM before cell plating.
Immunofluorescence and imaging. Samples were fixed and labelled as previously described 29 , with multiple independent fields imaged on a Zeiss LSM 510 microscope system with either a 20× Apo NA 0.75 air or 40× Apo LWD NA 1.15 water objective and 488 nm argon, 543 nm HeNe, and 633 nm HeNe excitation lines.
Clinical data analysis. Previously published and reanalysed microarray data were obtained from the TCGA Research Network (http://cancergenome.nih.gov) and downloaded from the CBio Portal for Cancer Genomics (http://www.cbioportal.org/ public-portal/index.do) under the Low Grade Glioma 1 and the Glioblastoma Multiforme [17] [18] [19] data sets, with mean normalized expression scores (z scores) for genes of interest determined. Statistical significance of differences was determined using a two-tailed Mann-Whitney test, with P < 0.05 considered to be significant.
Genes used in the hypoxia gene signature include: ANXA2, BTG1, CA9, EDN1, EGR1, HMOX1, IER3, LDHA, LGAL3, LOXL2, PDK1, SLC2A1, TFRC, VDAC1 and VEGFA.
Statistics and reproducibility.
All quantitative results were assessed by unpaired Student's t-test after confirming that the data met appropriate assumptions (normality, homogeneous variance, and independent sampling), non-parametric Wilcox/Mann-Whitney exact test (using the normal approximation for the U score), or the Kolmogorov-Smirnov distribution test (α = 0.05), all two-tailed. Unless otherwise indicated, all data were plotted with standard deviation error bars, and variances between groups being statistically compared are similar. For AFM mechanical testing of clinical specimens, multiple regions were assessed (10 regions per patient), and regions were pooled per patient to establish a mean Young's modulus per patient; statistical analysis was performed on patient means (unless otherwise noted). Animal cohort and in vitro sample sizes were chosen to provide 85% power to detect an effect size of 2.5 with a two-sided error of less than or equal to 5%. All results were reproduced at least twice in the laboratory and the n-value denotes the sample size used in statistical testing. Graphpad/Prism software was used to conduct the statistical analysis of the data. P values less than or equal to 0.05 were considered to be significant. For animal studies, animals were randomly distributed among the different conditions by the investigator since the animals did not exhibit any size or appearance differences at the onset of the experiments. No animals were excluded. For mouse and clinical studies, mechanical testing was performed blinded and immunostaining intensity of tissue sections was scored blinded.
Data availability. Previously published microarray data 1, 17, 18 that were reanalysed here are available from the TCGA Research Network (http:// cancergenome.nih.gov) via download from the CBio Portal for Cancer Genomics (http://www.cbioportal.org/public-portal/index.do) under the Low Grade Glioma Representative AFM testing grid <50Pa <500Pa
Supplementary Figure 6 Regional assessment of ECM stiffness and mechanosignaling. a, Maps of ECM stiffness are obtained using an AFM tip where a 5µm diameter bead is attached to the end of a cantilever. The AFM tip was brought down to indent the sample, during which the motion of the z-piezo and the applied force were recorded. The ECM stiffness was computed from the displacement of the z-piezo minus the bending of the cantilever. The number of ECM stiffness measurements made was operator-determined by the x-and y-step sizes input for a 90µm by 90µm grid. The example shown demonstrates how step sizes of 14 (in the xand y-directions) result in 196 independent mechanical measurements. b, For regionally-matched correlations between ECM stiffness and mechanosignaling, patient (and xenograft) tissues were immunostained for TNC (green) and pFAK (red). Multiple specific, patient-representative regions (4-10 regions per tumor) were identified (with the x-and y-coordinates noted and images acquired) for further AFM testing in a serial section. For subsequent AFM testing, after patient (and xenograft) tumor sections were secured for testing, the identified testing region was located via x-and y-coordinates using the optical microscope. c, Left: Immunohistochemistry images of patient tumors immunostained for TNC (green) and pFAK (red) with DAPI (blue) with regions for AFM analysis in serial sections denoted by white boxes. Graphs illustrate individual patient correlations between TNC and pFAK. Right: AFM maps of patient tumors. Graphs illustrate individual patient correlations between elastic modulus (stiffness) and pFAK. d, The data underlying (c left) was combined into graphs depicting regional matching of ECM stiffness and pFAK (left) and TNC and pFAK (right) to illustrate not only the correlations between the variables, but also the variability between patients within the cohort (n=3 patient samples/ group, One-way ANOVA with Tukey's comparison P=0.0011). e, The data underlying (c right) was combined into a graph depicting both the patient-specific trends in elastic modulus (stiffness) and the patient variability within the cohort (n=10 patients, 4 regions/patient sample, linear regression analysis yielding p<0.0001 for both plots with R2=0.4812 for pFAK:stiffness data and R2=0.5850 for pFAK:TNC data). Scale Bars 200μm (left panels) and 20μm (right panels), as indicated. 
